Clinicopathological and Functional Implications of the Inhibitor of Apoptosis Proteins Survivin and XIAP in Esophageal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Feb 23

PMID 29467895

Citations 17

Authors

Levent Dizdar

Lisa M Junemann

Thomas A Werner

Pablo E Verde

Stephan E Baldus

Nikolas H Stoecklein

Wolfram T Knoefel

Andreas Krieg

Affiliations

Soon will be listed here.

Abstract

Based on their overexpression and important roles in progression and therapy-resistance in malignant diseases, the inhibitor of apoptosis protein family (IAP) members, survivin and X-linked inhibitor of apoptosis protein (XIAP), represent attractive candidates for targeted therapy. The present study investigated the prognostic and biological relevance of survivin and XIAP in esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Survivin and XIAP expression was analyzed by immunohistochemistry using tissue microarrays containing 120 ESCC and 90 EAC samples as well as the corresponding non-neoplastic esophageal mucosa samples. IAP expression levels were then correlated to clinicopathological parameters and overall survival to identify any associations. In addition, esophageal cancer cell lines were treated with the survivin inhibitor YM155, and the XIAP inhibitors Birinapant and GDC-0152 . Survivin and XIAP expression were significantly increased in EAC and ESCC when compared with tumor-adjacent mucosa. In patients with ESCC XIAP expression was associated with female gender and advanced tumor stages, and nuclear survivin expression was associated with poor grading. High XIAP expression was identified as an independent negative prognostic marker in ESCC. By contrast, XIAP inhibitors did not affect cancer cell viability , and the small molecule survivin inhibitor YM155 significantly reduced cell viability and proliferation in esophageal cancer cell lines. Western blot analysis revealed a dose dependent decrease of survivin accompanied by an increased poly (adenosine diphosphate-ribose) polymerase cleavage following YM155 treatment. These findings underline the potential role of survivin and XIAP in the oncogenesis of esophageal cancer and provide a rationale for future clinical studies investigating the therapeutic efficacy of IAP directed therapies in patients with esophageal cancer.

Citing Articles

Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.

Stevenson L, Cairns L, Li X, Jammula S, Taylor H, Douglas R Sci Rep. 2024; 14(1):32121.

PMID: 39739112 PMC: 11686190. DOI: 10.1038/s41598-024-83912-4.

STRAP Knockdown Inhibits Migration and Growth of Non-Small Cell Lung Cancer.

Chen X, Xu C, Yang Y, Li L, Hong R Bull Exp Biol Med. 2024; 177(6):780-786.

PMID: 39455498 DOI: 10.1007/s10517-024-06267-w.

Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway.

Liu Y, Li F, Wang Q, Zhang Y, Tian S, Li B Discov Oncol. 2024; 15(1):134.

PMID: 38678128 PMC: 11055845. DOI: 10.1007/s12672-024-00995-1.

Amano S, Hirashita T, Kawano Y, Nishida H, Orimoto H, Kawamura M World J Surg Oncol. 2023; 21(1):381.

PMID: 38082268 PMC: 10714622. DOI: 10.1186/s12957-023-03267-4.

Subcellular localization of X-linked inhibitor of apoptosis protein (XIAP) in cancer: Does that matter?.

Mendonca B, Ferreira C, Maia R, Nestal de Moraes G BBA Adv. 2023; 2:100050.

PMID: 37082602 PMC: 10074912. DOI: 10.1016/j.bbadva.2022.100050.

References

Pohl H, Welch H . The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97(2):142-6. DOI: 10.1093/jnci/dji024. View

Dohi T, Xia F, Altieri D . Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 2007; 27(1):17-28. PMC: 1986705. DOI: 10.1016/j.molcel.2007.06.004. View

Xia H, Chen S, Huang H, Ma H . Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. Clin Chim Acta. 2015; 446:82-5. DOI: 10.1016/j.cca.2015.04.009. View

Altieri D . New wirings in the survivin networks. Oncogene. 2008; 27(48):6276-84. PMC: 2683067. DOI: 10.1038/onc.2008.303. View

Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A . Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012; 3(2):179-97. PMC: 3388737. View

Benetatos C, Mitsuuchi Y, Burns J, Neiman E, Condon S, Yu G . Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014; 13(4):867-79. DOI: 10.1158/1535-7163.MCT-13-0798. View

Wu G, Chai J, Suber T, Wu J, Du C, Wang X . Structural basis of IAP recognition by Smac/DIABLO. Nature. 2001; 408(6815):1008-12. DOI: 10.1038/35050012. View

Altieri D . Survivin - The inconvenient IAP. Semin Cell Dev Biol. 2015; 39:91-6. PMC: 4410054. DOI: 10.1016/j.semcdb.2014.12.007. View

Liu Z, Sun C, Olejniczak E, Meadows R, Betz S, Oost T . Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 2001; 408(6815):1004-8. DOI: 10.1038/35050006. View

10.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View

11.

Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M . Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun. 2012; 425(4):711-6. DOI: 10.1016/j.bbrc.2012.07.103. View

12.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

13.

Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S . XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther. 2007; 6(6):973-80. DOI: 10.4161/cbt.6.6.4195. View

14.

Zhou S, Ye W, Shao Q, Qi Y, Zhang M, Liang J . Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy. World J Surg Oncol. 2013; 11:288. PMC: 3819256. DOI: 10.1186/1477-7819-11-288. View

15.

Fulda S . Smac mimetics as IAP antagonists. Semin Cell Dev Biol. 2015; 39:132-8. DOI: 10.1016/j.semcdb.2014.12.005. View

16.

Bai L, Smith D, Wang S . Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther. 2014; 144(1):82-95. PMC: 4247261. DOI: 10.1016/j.pharmthera.2014.05.007. View

17.

Fulda S . Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene. 2013; 33(6):671-6. DOI: 10.1038/onc.2013.63. View

18.

Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, STEIN H, Hopfner M . Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003; 88(1):115-9. PMC: 2376783. DOI: 10.1038/sj.bjc.6600696. View

19.

Werner T, Tamkan-Olcek Y, Dizdar L, Riemer J, Wolf A, Cupisti K . Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma. Br J Cancer. 2016; 114(4):427-34. PMC: 4815780. DOI: 10.1038/bjc.2016.5. View

20.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View